PARTIE 2: LE RESVERATROL, MOLECULE NATURELLE D'AVENIR POUR LE TRAITEMENT DU CANCER
4 Conclusion
L'énorme quantité d'études cliniques et animales suggère que le resvératrol peut avoir des effets bénéfiques pour améliorer la santé, prévenir et / ou traiter les maladies chroniques chez l'homme. Cependant, malgré une grande quantité de preuves circonstancielles et
expérimentales, les études cliniques définitives manquent largement. En outre, l'explication de la base moléculaire des résultats bénéfiques du resvératrol attend encore d'autres études épidémiologiques détaillées et approfondies. D'autres études sont nécessaires concernant les facteurs génétiques qui expliquent les différences dans la biodisponibilité et les réponses physiologiques au resvératrol entre les individus. Il convient de préciser si le resvératrol peut avoir des effets synergiques ou additifs en combinaison avec d'autres thérapies.
121
BIBLIOGRAPHIE
PRESENTATION
1: Takaoa,M,1939 Resveratrol a new phenolic compound from veratrum grandiflorum. Nippon Kagaku Kaishi 60, 1090-1100.
2: Nonomura, S, Kanagawa, H,Makimoto, A.1963. Chemical constituant of polygonaceous plants.Studies on the components of Ko-jo-kon.Yakugaku Zasshi 83, 988-990.
3: Lan 1959 et state administration of traditional chinese medicine 4:Zhang et al., 2006; Benova et al, 2008. Liang and Zov, 2011. 5: Siemann et Creasy, 1992.
6: S.Renaud, Michel de Lorgeril. Wine, alcohol, platelets and the french paradox for coronary heart deseases. Lancet vol 339 n°8808,1992, p1523-1526.
7: Douillet-Breuil et Coll 1999 8: Deluc et Coll 2011
9: Alfonso Carrascosa,Rosario Munoz, Ramon Gonzalez Garcia, Elsevier 2011 ISBN: 9780123750211
10:Effects of resveratrol on the ultrastructure of Botrytis cinerea conidia and biologicas significance in plant/pathogen interaction. Marielle Adrian, Philippe Jeandet.
11:Goldberg et Coll 2003
12: Investigation of the absorption of resveratrol oligomers in the caco-2 cellular model of intestinal absorption. Ina willenberg, Maria Michael, Jasmin Wonik, Laura C.Bartel, Michael T Empl, Nils Helge
13:Henry vitrat et coll 2006 14: Juan et coll 2009
15 : Bioavailability of resveratrol
Thomas Walle Department of Pharmacology, Medical University of South Carolina, Charleston, South Carolina Address for correspondence: Thomas Walle, Department of Pharmacology, Medical
University of South Carolina, Charleston, SC 29425.
16 : Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Zhu W1, Qin W, Zhang K, Rottinghaus GE, Chen YC, Kliethermes B, Sauter ER 17: Optimization of trans-Resveratrol bioavailability for human therapy.
Amiot MJ1, Romier B, Dao TM, Fanciullino R, Ciccolini J, Burcelin R, Pechere L, Emond C,
122
PARTIE 1 : LE RESVERATROL A L’OFFICINE :
18 : A new insight into resveratrol as an atheroprotective compound: Inhibition of lipid peroxidation and enhancement of cholesterol efflux.
Hicham Berrouguia,b,c, Guillaume Greniera,d, Soumaya Loueda,b, Geneviève Drouina,d, Abdelouahed Khalila.
19: Khalil A, Fortin Jp, LeHoux JG, Fulop T. Age related decrease of dehydroepiandrosterone concentrations in low density lipoproteins and its role in the susceptibility of low density lipoproteins to lipid peroxidation. J lipid Res 2000 ;41 :1552-61.
20: Bonnefont-Rousselot D. Gamma radiolysis as a tool to study lipoprotein oxidation mechanisms. Biochimie 2004 ; 86 : 903-11.
21. Resveratrol scavenges reactives oxygen species and effects radical induced responses 22: Resveratrol, a Natural Phenolic Compound May Reduce Carbonylation Proteins Induced by Peroxynitrite in Blood Platelets
B. Olas, P. Nowak, M. Ponczek and B. Wachowicz
Department of General Biochemistry, Institute of Biochemistry, University of Lodz, Poland
23: Resveratrol Inhibits Cyclooxygenase-2 Transcription and Activity in Phorbol Ester-treated Human Mammary Epithelial Cells*
(Received for publication, March 24, 1998, and in revised form, June 22, 1998)
Kotha Subbaramaiah, Wen Jing Chung‡, Pedro Michaluarti, Nitin Telang, Tadashi Tanabe**, Hiroyasu Inoue**, Meishiang Jang, John M. Pezzuto‡‡, and Andrew J. Dannenberg
24 : Das, S., Bertelli, A.A., Bertelli, A., Maulik,N., and Das, D.K., Anti inflammatory action of resveratrol : a novel mechanism of action. Drugs Exp.Clin. Res (in press).
25 : mecanisme de la protection cardiaque et vasculaire des polyphénols au niveau de l’endothélium . S.Martin, R.Andriantsitohaina. pharmaacologie et physico-chimie des interactions cellulaires et moléculaires, UMR CNRS 7034, faculté de pharmacie, université louis pasteur.
26 : the red wine phenolics trans resveratrol and quercetine block human platelet aggregation and eicosanoids synthesis : implications for protection against coronary heart disease. Clin.chim. Acta 235, 207-219 (1995)
27 :resveratrol a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells : a possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler.Throm.Vasc. Biol 19. 419-426 (1999)
28: resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells.J. Thromb Haemost.1.1089-1095 (2003)
29 : oral administration of resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protect isolated atriafrom menadione toxicity. Life.SCI. 72. 2741-2750 (2003).
30 : myocardial protection by phytokin, novel extract of trans-resveratrol and emodin. Free Radic.Res. 32, 135-144 (2000)
123
31: Mestre, J. R., Subbaramaiah, K. Sacks, P. G., Schantz, S. P., Tanabe, T., Inoue, H., and Dannenberg, A.J. (1997) Cancer res 57, 1081-1085.
32 : resveratrol incardioprotection : a therapeutic promise of alternative medicine . Dipak K. Das and Nilanjana Maulik : cardiovascular research center, university of connecticut school of medicine farmington , CT 06030-1110.
33 : Src tyrosine kinases is the trigger but not the mediator of ischemic preconditioning. Am.J.Physiol 281,H1066-H1074 (2001)
34 : induction ofiNOS expression by monophosphoryl lipid A : a pharmacological approach for myocardial adaptation to ischemia.Drugs Exp Clin. Res. 24, 117-124.
35: anti-inflammatory effects of resveratrol occur via inhibition of lipopolysaccharide-induced NF-kB activation in Caco-2 and SW480 human colon cancer cells. Maria antonietta panaro, Vito carofiglio, Angela acquefredda, Pasqua cavallo and Antonia cianciulli. Department onf human anantomy and histology, university of Bari, Piazza Giulio Cesare 11, policlinico I-70124 Bari Italy
British journal of nutrition (2012) 108, 1623-1632
36: Maier-Salamon A, Hagenauer B, Wirth M, et al (2006) Increase transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm res 23, 2107-2115.
37: Goldberg DM, Yan J & Soleas GJ (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36, 79–87.
38: Rahman I, Biswas SK & Kirkham PA (2006) Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 72, 1439–1452.
39:Martı ´n AR, Villegas I, Sa ´nchez-Hidalgo M, et al. (2006) The effects of resveratrol, a
phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 147, 873–885.
40:Tsai SH, Lin-Shiau SY & Lin JK (1999) Suppression of nitric oxide synthase and the down- regulation of the activation of NF-kB in macrophages by resveratrol. Br J Pharmacol 126, 673–680. 41:Wadsworth TL & Koop DR (1999) Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264·7 macrophages. Biochem Pharmacol 57, 941–949 42:Murakami A, Matsumoto K, Koshimizu K, et al. (2003) Effects of selected food factors with chemopreventive properties on combined lipopolysaccharide- and interferon-induced kB degradation in RAW264·7 macrophages. Cancer Lett 195, 17–25.
43:effect of apigenin, kaempferol and resveratrol on the gene expression and protein secretion of tumor necrosis factor alpha and interleukin-1 (IL-10) in RAW-264.7 macrophages. Marta Palacz- Wrobel, Paulina Borkowska, Monika Paul-Samojedny,Malgorzata Kowalczyk, Anna Fila-Danilow, Renata Suchanek-Raif, Jan Kowalski Silesian Medical College in Katowice, ul. Mickiewcza 29,40- 085, Katowice, Poland.
44:Z.H.Ma, Q.Y.Ma, L.C. Wang,H.C.Sha,S.L.Wu,M.Zhang, Effect of resveratrol on NF-kappaB activity in rat peritoneal macrophages, Am.J.Chin.Med 34(2006) 623-630.
45:J.Kowalski,A.Samojedny,M.Paul,G.Pietsz,T.Wilczok, Effect of apigenin, Kaempferol and resveratrol on the expression of interleukin-1beta and tumor necrosis factor alpha genes in J774.2 macrophages, Pharmacol.Rep.57(2005) 390-394
124
46:Resveratrol Interferes with IL1-β-Induced Pro-Inflammatory Paracrine Interaction between Primary Chondrocytes and Macrophages
Emeric Limagne 1,2,3, Allan Lançon 1,2, Dominique Delmas 1,3, Mustapha Cherkaoui-Malki 1,2 and Norbert Latruffe 1,2,* 1 Laboratoire de Lipides, Nutrition, Cancer, Université de Bourgogne-Franche Comté, Dijon F21000, France
47:Resveratrol distinctively modulates the inflammatory profiles of immune and endothelial cells Joseph Schwager*, Nathalie Richard, Franziska Widmer and Daniel Raederstorff
48:Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002;39:531– 6.
49:Mauer J, Chaurasia B, Goldau J, Vogt MC, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesityassociated resistance to insulin. Nat Immunol. 2014;15:423–30.
50:Bakker GC, van Erk MJ, Pellis L, Wopereis S, et al. An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach. Am J Clin Nutr. 2010;91:1044–59.
51 : Microbiotes and metabolic diseases: the bases for therapeutic strategies 2016 Nov;32(11):952- 960. doi: 10.1051/medsci/20163211010. Epub 2016 Dec 23. Burcelin R, Nicolas S, Blasco-Baque V.
52: Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet- induced obesity and diabetes in mice. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Diabetes. 2008 Jun ; 57(6):1470-81.
53 : The indigenous gastrointestinal microflor.Trends in Microbiology, 4 (1996), pp. 430-435 54 : Gut microbiota, obesity and metabolic disorders. Minerva Gastroenterol Dietol. 2017 Dec;63(4):337-344. doi: 10.23736/S1121-421X.17.02376-5. Federico A, Dallio M, DI Sarno R, Giorgio V, Miele L
55: Huang H, Liu T, Rose JL, Stevens RL, Hoyt DG.Sensitivity of mice to lipopolysaccharide is increased by a high saturated fat and cholesterol diet.J Inflamm (Lond). 2007;4:22.
56 : Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpice T, Chamontin B, Ferrieres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burce-lin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772.
57 : Dao TM, Waget A, Klopp P, et al Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One 2011;6:e20700pmid:21673955 58 : Cani PD, Amar J, Iglesias MA, et al Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761–1772pmid:17456850
59 : Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity Yi Qiao, Jin Sun, Shufang Xia, Xue Tang, Yonghui Shia and Guowei Le.
125
PARTIE 2 : LE RESVERATROL, ALTERNATIVE NATURELLE
D’AVENIR DANS LE TRAITEMENT DU CANCER ET DES
MALADIES NEURODEGENERATIVES :
1 : Sporn MB (2011) Perspective:the big C for Chemoprevention.Nature 471 S10-S1
2 : Catagol B, Batirel S,Taga Y, Ozer NK (2012) Resveratrol: French paradox revisited.front pharmacol 3:141
3 : Jang M,Cai L, Udeani GO, et al. 1997 Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science 275: 218-20
4 : Athar M, Back JH, Kopelovich L, Bickers, et al. (2009) Multiple molecular targets of resveratrol : anti carcinogenic mechanisms. Arch Biochem Biophys 486:95-102
5 : Godvadze V,Orrenisu S,Zhivotovsky B (2008) Mitochondria in cancer cells : what is so special about them? Trends Cells Biol 18: 165-73
6 : Zini R, Morin C, Bretelle A, et al (1999) Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res 25:87-97
7 : Rubiolo JA, Miteux G,Vega FV (2008) Resveratrol protects primary rat hepatocytes against oxidative stress damage:activation of the Nrf2 transcription factor and augmented activities of antioxydant enzymes .Eur J Pharmacol 591:66-72
8 : Zhang Q, Tang X, Lu QY, et al (2005) Resveratrol inhibits hypoxia-induced accumulation of hypoxia inducible faror 1alpha and VGEF expression in human tongue squamous cell carcinoma and hepatoma cells.Mol Cancer There 4:1465-74
9 : Faber AC, Dufort FJ, Blair D, et al. (2006) Inhibition of phosphatidylinositol 3-kinasemediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem Pharmacol 72: 1246–1256
10 : Iqbal MA, Bamezai RN (2012) Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS One 7: e36764
11 : Lunt SY, Vander-Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27: 441–464
12 : Iqbal MA, Bamezai RN (2012) Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS One 7: e36764
13 : Kueck A, Opipari AW Jr, Griffith KA, et al. (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol 107: 450–457
14 : Lagouge M, Argmann C, Gerhart-Hines Z, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109– 1122
15 : Park SJ, Ahmad F, Philp A, et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421–433
126
16 : Um JH, Park SJ, Kang H, et al. (2009) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554–563
17 : Pietrocola F, Marino G, Lissa D, et al. (2012) Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. Cell Cycle 11: 3851–3860
18 : Howitz KT, Bitterman KJ, Cohen HY, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191–196
19 : Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13: 251–262
20 : Canto C, Jiang LQ, Deshmukh AS, et al. (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 11: 213–219
21 : Rodgers JT, Lerin C, Haas W, et al. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113–118
22 : Faubert B, Boily G, Izreig S, et al. (2012) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17: 113–124
23 : Brown VA, Patel KR, Viskaduraki M, et al. (2010) Repeat dose study of the cancer
chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70: 9003–9011
24 : Nguyen AV, Martinez M, Stamos MJ, et al. (2009) Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res 1: 25–37
25 : Patel KR, Brown VA, Jones DJ, et al. (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70: 7392–7399
26 : Zhu W, Qin W, Zhang K, et al. (2012) Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer 64: 393–400
27 : Howells LM, Berry DP, Elliott PJ, et al. (2011) Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 4: 1419–1425
28 : Chow HH, Garland LL, Hsu CH, et al. (2010) Resveratrol modulates drug — and carcinogen — metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3: 1168–1175
29 : Detampel P, Beck M, Krahenbuhl S, Huwyler J (2012) Drug interaction potential of resveratrol. Drug Metab Rev 44: 253–265
30 : D.Lissa,M.Castedo, Effets préventifs et sensibilisants du resvératrol dans le cancer.Oncologie (2013) 15: 474-479
31 : Gupta SC, Kannappan R, Reuter S, et al. (2011) Chemosensitization of tumors by resveratrol. Ann NY Acad Sci 1215: 150–160
32 : Vinod BS, Maliekal TT, Anto RJ (2012) Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance. Antioxid Redox Signal 18: 1307–1348
33 : Kweon SH, Song JH, Kim TS (2010) Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 395: 104–110
127
34 : Ivanov VN, Partridge MA, Johnson GE, et al. (2008) Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 314: 1163–1176
35 : Shankar S, Chen Q, Siddiqui I, et al. (2007) Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4′, 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J Mol Signal 2: 7
36 : Ahmad KA, Clement MV, Hanif IM, Pervaiz S (2004) Resveratrol inhibits druginduced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 64: 1452–1459
37 : Fukui M, Yamabe N, Zhu BT (2010) Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer 46: 1882–1891
38 : Mao QQ, Bai Y, Lin YW, et al. (2010) Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol Nutr Food Res 54: 1574–1584
39 : Deenen MJ, Cats A, Beijnen JH, Schellens JH (2011) Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist 16: 820–834
40 : Goetz MP, Rae JM, Suman VJ, et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23: 9312–9318
41 : Przedborski, S., Vila, M., & Jackson-lewis, V. (2003). Neurodegeneration : What is it and where are we ? J. Clin. Invest. 111:3–10
42 : Mok, W., Chow, T. W., Zheng, L., Mack, W. J., & Miller, C. (2004). Clinicopathological concordance of dementia diagnoses by community versus tertiary care clinicians, Am J. Alzheimer’s Dis Other Demen. 19(3), 161–165.
43 : Nieoullon, A. (2011). Neurodegenerative diseases and neuroprotection : current views and prospects. J Appl Biomed. 9: 173–183.
44 : Brown, R. C., Lockwood, A. H., & Sonawane, B. R. (2005). Neurodegenerative Diseases: An Overview of Environmental Risk Factors, Environ. Health Perspect 1250(9), 1250–1256.
45 : Esch, T., Stefano, GB., Fricchione, GL., & Benson, H. (2002). The role of stress in neurodegenerative diseases and mental disorders. Neuro endocrinol lett. 23(3): 199-208.
46 : Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., … Hodgson, R. (2017). Protein misfolding in neurodegenerative diseases : implications and strategies. Translational
Neurodegeneration. 1–13.
47 : Forman, M. S., Trojanowski, J. Q., & Lee, V. M. (2004). Neurodegenerative diseases : a decade of discoveries paves the way for therapeutic breakthroughs, Nature med. 10(10), 1055–1063.
48 : Kumar, V., Sami, N., Kashav, T., Islam, A., Ahmad, F., & Hassan, I. (2016). Protein aggregation and neurodegenerative diseases: from theory to therapy. Eur J. Med Chem.
49 : Mattson, M. P. (2000). Apotosis in Neurodegenerative disorders. Nature Reviews. 1, 120–129. 50 : Andersen, J. K. (2004). Oxidative stress in neurodegeneration : cause or consequence ? Nature Reviews Neurosci, supp. Vol 5, 18–25.
51 : Wang, J., & Maldonado, M. A. (2006). The Ubiquitin-Proteasome System and Its Role in Inflammatory and Autoimmune Diseases, Cell Mol Immunol 3(4), 255–261.
128
52 : D'après Forman, M. S., Trojanowski, J. Q., & Lee, V. M. (2004), adapté par Thibaut Burg,Nature et Médecine.
53 : http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-chroniques-et- traumatismes/Maladies-neurodegeneratives/Les-maladies-neurodegeneratives
54 : http://www.gouvernement.fr/action/le-plan-maladies-neuro-degeneratives-2014-2019
55 : Le Resvératrol, chef de file de l’anti âge en nutri-dermocosmétique : le bilan Dr Eric Seree,INRA 1260,Décembre 2011.
56 : D'après Forman, M. S., Trojanowski, J. Q., & Lee, V. M. (2004), adapté par Thibaut Burg,Nature et médecine
57 : les maladies neurodégnératives par Thibaut Burg 2017, Planet Vie ENS eduscol. 58 : Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., and
Takada, Y. (2004). Role of resveratrol in prevention and therapy of can- cer: preclinical and clinical studies. Anticancer Res. 24, 2783–2840.
Anekonda, T. S. (2006). Resveratrol – a boon for treating Alzheimer’s dis- ease? Brain Res. Rev. 52, 316–326.
Bourdon, J. C. (2007). p53 and its iso- forms in cancer. Br. J. Cancer 97, 277–282.
De Lédinghen, V., Monvoisin, A., Neaud, V., Krisa, S., Payrastre, B., Bedin, C., Desmouliere, A., Bioulac-Sage, P., and Rosenbaum, J. (2001). Trans -resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor- induced invasion of hepatocellular carcinoma cells. Int. J. Oncol. 19, 83–88.
Delmas, D., Jannin, B., Cherkaoui, M. M., and Latruffe, N. (2000). Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol. Rep. 7, 847–852.
Deng, C. X. (2009). SIRT1, is it a tumor promoter or tumor suppressor? Int. J. Biol. Sci. 5, 147–152.
Francy-Guilford, J., and Pezzuto, J. M. (2008). Mechanisms of cancer chemopreventive agents: a perspec- tive. Planta Med. 74, 1644–1650.
Karuppagounder, S. S., Pinto, J. T., Xu, H., Chen, H. L., Beal, M. F., and Gib- son, G. E. (2009). Dietary supple- mentation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neu- rochem. Int. 54, 111–118.
Khanduja, K. L., Bhardwaj, A., and Kaushik, G. (2004). Resveratrol inhibits N-nitrosodiethylamine- induced ornithine decarboxylase and cyclooxygenase in mice. J. Nutr. Sci. Vitaminol. 50, 61–65.
129
Kumar, P., Padi, S. S., Naidu, P. S., and Kumar, A. (2006). Effect of resver- atrol on 3-nitropropionic acid- induced biochemical and behav- ioural changes: possible neuropro- tective mechanisms. Behav. Pharma- col. 17, 485–492.
Kundu, J. K., and Surh, Y. J. (2008). Can- cer chemopreventive and therapeu- tic potential of resveratrol: mecha- nistic perspectives. Cancer Lett. 269, 243–261.
Kuo, P. L., Chiang, L. C., and Lin, C. C. (2002). Resveratrol- induced apop- tosis is mediated by p53- dependent pathway in Hep G2 cells. Life Sci. 72, 23–34.
Lin, H. Y., Tang, H. Y., Davis, F. B., and Davis, P. J. (2011). Resveratrol and apoptosis. Ann. N. Y. Acad. Sci. 1215, 79–88.
Marambaud, P., Zhao, H., and Davies, P. (2005). Resveratrol promotes clear- ance of Alzheimer’s disease amyloid- beta peptides. J. Biol. Chem. 280, 37377–37382.
Martin, K. R. (2006). Targeting apopto- sis with dietary bioactive agents. Exp. Biol. Med. (Maywood) 231, 117–129
Michels, G., Watjen, W., Weber, N., Nier- ing, P., Chovolou, Y., Kampkotter, A., Proksch, P., and Kahl, R. (2006). Resveratrol induces apoptotic cell death in rat H4IIE hepatoma cells but necrosis in C6 glioma cells. Tox- icology 225, 173–182.
Miyashita, T., Krajewski, S., Krajew- ska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799–1805.
75 Saikumar, P., Dong, Z., Mikhailov, V., Denton, M., Weinberg, J. M., and Venkatachalam, M. A. (1999). Apop- tosis: definition, mechanisms, and relevance to disease. Am. J. Med. 107, 489–506.
Sharma, M., and Gupta, Y. K. (2002). Chronic treatment with trans resver- atrol prevents
intracerebroventricu- lar streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci. 71, 2489–2498.
Tsujii, M., and DuBois, R. N. (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overex- pressing prostaglandin endoperox- ide synthase 2. Cell 83, 493–501.
Yang, Y. B., and Piao, Y. J. (2003). Effects of resveratrol on secondary dam- ages after acute spinal cord injury in rats. Acta Pharmacol. Sin. 24, 703–710.
130